Loading
No company can profit from a drug for a cancer that affects a few hundred people. A guaranteed payment for success would change that calculation.
Rare and paediatric cancers lack markets, and existing incentives (orphan designation, priority review vouchers, the proposed transferable exclusivity vouchers) are criticised for poor targeting and high cost to payers. A directly funded prize or advance market commitment, paid on achieving a pre-specified clinical benefit in a named rare indication, targets the payment to the outcome and avoids distorting prices elsewhere.
Shares Funding follows fashion, not burden, Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Incentives reward me-too drugs and marginal gains, Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Neuroblastoma (paediatric), National Cancer Institute (NIH), Sarcomas (soft tissue, bone, GIST).
Shares Funding follows fashion, not burden, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, National Cancer Institute (NIH), Sarcomas (soft tissue, bone, GIST).
Shares Incentives reward me-too drugs and marginal gains, Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Incentives reward me-too drugs and marginal gains, Funding follows fashion, not burden.
Shares Funding follows fashion, not burden, National Cancer Institute (NIH).